PKO Investment Management Joint Stock Co Buys 1,400 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

PKO Investment Management Joint Stock Co raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 30.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 6,000 shares of the medical research company's stock after acquiring an additional 1,400 shares during the period. PKO Investment Management Joint Stock Co's holdings in Thermo Fisher Scientific were worth $2,986,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Semus Wealth Partners LLC boosted its position in shares of Thermo Fisher Scientific by 4.0% during the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock valued at $245,000 after purchasing an additional 18 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Proactive Wealth Strategies LLC boosted its position in shares of Thermo Fisher Scientific by 2.7% during the 4th quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company's stock valued at $392,000 after purchasing an additional 20 shares in the last quarter. Cassaday & Co Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 0.9% during the 4th quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock valued at $1,189,000 after purchasing an additional 20 shares in the last quarter. Finally, Callan Capital LLC boosted its position in shares of Thermo Fisher Scientific by 2.7% during the 4th quarter. Callan Capital LLC now owns 773 shares of the medical research company's stock valued at $402,000 after purchasing an additional 20 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. UBS Group reduced their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Barclays decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Citigroup decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Finally, Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $605.30.

Thermo Fisher Scientific Stock Up 0.6%

NYSE TMO traded up $2.28 during trading on Thursday, reaching $392.54. The company's stock had a trading volume of 2,883,201 shares, compared to its average volume of 1,944,785. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $148.18 billion, a PE ratio of 23.02, a PEG ratio of 2.07 and a beta of 0.78. The business has a 50-day moving average price of $413.43 and a 200-day moving average price of $488.79. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company's revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the company earned $5.11 earnings per share. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.